Granulomatous infections due to tumor necrosis factor blockade: correction.
Robert S
RS
Wallis
Michael
M
Broder
John
J
Wong
David
D
Beenhouwer
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000068800:Etanercept; D006105:Granulomatous Disease, Chronic / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept